Understanding the Evolving Role of Immunotherapy in the Treatment of Malignant Melanoma CME

Steven J. O'Day, MD; Jedd D. Wolchok, MD, PhD Author Information and Disclosures

Release Date: February 29, 2008; Valid for credit through March 1, 2009

Credits Available
Physicians - maximum of 1.0 AMA PRA Category 1 Credit(s)™ for physicians

This program was created specifically for use on Medscape.

To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

Contents of This CME Activity

Legal Disclaimer

The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Copyright © 2008 education | outcomes | science.
BMS, Medarex
Learning Objectives
Upon completion of this activity, participants should be able to:
  1. Outline the basic principles of tumor immunology and their application to malignant melanoma treatment
  2. Describe the MOAs of emerging immunotherapies for malignant melanoma
  3. Summarize the safety and efficacy results of clinical trials with novel immunotherapies for malignant melanoma
  4. Determine the implications of emerging immunotherapies for disease management
  5. Describe challenges regarding the integration of new immunotherapies into clinical practice for the purpose of improving patient outcomes and identifying potential strategies to address these issues
Author Disclosures
Steven J. O'Day, MD
Disclosure: Dr. O'Day: Advisor/speaker: Bristol-Myers Squibb Company. Research: Medarex, Inc.

Jedd D. Wolchok, MD, PhD
Disclosure: Dr. Wolchok: Advisor/speaker: Bristol-Myers Squibb Company, Schering-Plough Corporation.
 
education | outcomes | science
education | outcomes | science is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

education | outcomes | science designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The American Medical Association has determined that non-US licensed physicians who participate in this CME activity are eligible for AMA PRA Category 1 Credit™.

This activity is provided free of charge to participants.

In order to receive credit, practitioners must participate in the activity and complete the evaluation form and post-test. Upon successful completion of the online assessments, you may download and print your certificate of credit.

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.